Daewoong Pharmaceutical Hosts 'Web Talk Show with the Korean Society for Bone and Mineral Research'

[Asia Economy Reporter Chunhee Lee] Daewoong Pharmaceutical announced on the 30th that it successfully concluded the 'Web Talk Show with the Korean Society for Bone and Mineral Research' held on the 26th.

This talk show was organized to share the latest information related to osteoporosis treatment with key executives of the Korean Society for Bone and Mineral Research under the theme of 'Treatment Strategies for Osteoporosis after Denosumab.' It was conducted live through the medical professional portal site 'Doctorville.' Approximately 2,500 medical professionals from related fields such as endocrinology and obstetrics and gynecology participated.

Professor Youngjoon Won of the Department of Endocrinology at Catholic Kwandong University (President of the Korean Society for Bone and Mineral Research) served as the moderator, while Professor Youngsang Kim of the Department of Family Medicine at Bundang CHA Hospital (Chairman of the Education Committee of the Korean Society for Bone and Mineral Research) was the speaker. Panelists included Professor Hanseok Choi of the Department of Endocrinology at Dongguk University and Professor Dongok Lee of the Department of Obstetrics and Gynecology at the National Cancer Center.

Professor Won stated, “As the number of osteoporosis patients continues to increase and society moves beyond aging into super-aging, it is necessary to consider long-term treatment strategies for osteoporosis, particularly how to use denosumab and bisphosphonate agents.”

Following this, Professor Kim, who gave a presentation, said, “In recent osteoporosis treatment, when discontinuing denosumab, the use of antiresorptive agents such as bisphosphonates is recommended to prevent rapid bone mineral density loss and vertebral fractures. Especially, according to recommendations from the European Calcified Tissue Society announced last January, zoledronate is known to be the most effective and appropriate.”

Lee Changjae, Vice President of Daewoong Pharmaceutical, said, “Although the number of osteoporosis patients in Korea has recently increased significantly, the two-year treatment adherence rate among osteoporosis patients remains low. Daewoong Pharmaceutical will continue to expand opportunities to share the latest information on osteoporosis treatment with medical professionals and will do its best to ultimately contribute to improving the treatment and quality of life of osteoporosis patients.”